×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Deciphera Pharmaceuticals Stock Forecast, Price & News

$13.26
+0.11 (+0.84%)
(As of 07/1/2022 03:59 PM ET)
Add
Compare
Today's Range
$12.76
$13.41
50-Day Range
$9.11
$13.98
52-Week Range
$6.51
$14.48
Volume
56,568 shs
Average Volume
1.16 million shs
Market Capitalization
$878.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.57

Deciphera Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.11 Rating Score
Upside/​Downside
100.4% Upside
$26.57 Price Target
Short Interest
Bearish
15.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.66
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$14.79 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.62) to ($1.70) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.47 out of 5 stars

Medical Sector

108th out of 1,428 stocks

Pharmaceutical Preparations Industry

35th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Deciphera Pharmaceuticals logo

About Deciphera Pharmaceuticals (NASDAQ:DCPH) Stock

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

DCPH Stock News Headlines

All Electric Commitment From GM, Volkswagen, Could Put Lithium Stock In A Supercycle
More automakers are pledging to go "fully electric" by 2035. NOW is the perfect time to get in on the "EV Revolution." And the best way to potentially do that, is to skip over the overvalued electric vehicle stocks...
A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Deciphera Pharmaceuticals Tops Q1 EPS by 10c
Deciphera Pharmaceuticals, Inc.(DCPH)
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DCPH
Fax
N/A
Employees
280
Year Founded
N/A

Company Calendar

Last Earnings
5/04/2022
Today
7/05/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$26.57
High Stock Price Forecast
$70.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+100.4%
Consensus Rating
Hold
Rating Score (0-4)
2.11111111111111
Research Coverage
9 Analysts

Profitability

Net Income
$-299,960,000.00
Net Margins
-279.96%
Pretax Margin
-284.95%

Debt

Sales & Book Value

Annual Sales
$96.15 million
Book Value
$5.21 per share

Miscellaneous

Free Float
63,502,000
Market Cap
$878.08 million
Optionable
Optionable
Beta
1.19














Deciphera Pharmaceuticals Frequently Asked Questions

Should I buy or sell Deciphera Pharmaceuticals stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Deciphera Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DCPH, but not buy additional shares or sell existing shares.
View analyst ratings for Deciphera Pharmaceuticals
or view top-rated stocks.

What is Deciphera Pharmaceuticals' stock price forecast for 2022?

9 brokerages have issued 1 year target prices for Deciphera Pharmaceuticals' stock. Their DCPH stock forecasts range from $6.00 to $70.00. On average, they anticipate Deciphera Pharmaceuticals' share price to reach $26.57 in the next twelve months. This suggests a possible upside of 100.4% from the stock's current price.
View analysts' price targets for Deciphera Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Deciphera Pharmaceuticals' stock price performed in 2022?

Deciphera Pharmaceuticals' stock was trading at $9.77 at the beginning of 2022. Since then, DCPH stock has increased by 35.7% and is now trading at $13.26.
View the best growth stocks for 2022 here
.

When is Deciphera Pharmaceuticals' next earnings date?

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Deciphera Pharmaceuticals
.

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) announced its earnings results on Wednesday, May, 4th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.03. The company earned $29.22 million during the quarter, compared to analysts' expectations of $27.17 million. Deciphera Pharmaceuticals had a negative trailing twelve-month return on equity of 79.96% and a negative net margin of 279.96%. The company's quarterly revenue was up 16.2% on a year-over-year basis. During the same quarter last year, the business posted ($1.06) EPS.
View Deciphera Pharmaceuticals' earnings history
.

Who are Deciphera Pharmaceuticals' key executives?

Deciphera Pharmaceuticals' management team includes the following people:
  • Mr. Steven L. Hoerter, Pres, CEO & Director (Age 51, Pay $1.01M)
  • Dr. Daniel L. Flynn Ph.D., Exec. VP, Chief Scientific Officer & Founder (Age 67, Pay $645.61k)
  • Mr. Thomas Patrick Kelly J.D., Exec. VP, CFO & Treasurer (Age 51, Pay $644.12k) (LinkedIn Profile)
  • Mr. Daniel C. Martin, Sr. VP & Chief Commercial Officer (Age 47, Pay $611.24k)
  • Dr. Matthew L. Sherman M.D., Exec. VP & Chief Medical Officer (Age 66, Pay $725.85k)
  • Dr. Stephen B. Ruddy Ph.D., Sr. VP & Chief Technical Officer (Age 58)
  • Ms. Jennifer Robinson, VP of Investor Relations
  • Mr. Jeffrey M. Held J.D., Sr. VP & Gen. Counsel
  • Ms. Jama Pitman, Sr. VP of Regulatory, Quality & Portfolio Management (Age 43)
  • Ms. Margarida Duarte, Sr. VP & Head of International

What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals CEO Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among Deciphera Pharmaceuticals' employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $13.26.

How much money does Deciphera Pharmaceuticals make?

Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $878.08 million and generates $96.15 million in revenue each year. The company earns $-299,960,000.00 in net income (profit) each year or ($4.89) on an earnings per share basis.

How many employees does Deciphera Pharmaceuticals have?

Deciphera Pharmaceuticals employs 280 workers across the globe.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for Deciphera Pharmaceuticals is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at eciphera@argotpartners.com.

This page (NASDAQ:DCPH) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.